<DOC>
	<DOCNO>NCT01599130</DOCNO>
	<brief_summary>For HBeAg ( + ) hepatitis B patient treat entecavir 48 week without HBeAg loss , switch peg-interferon may increase response rate . In investigator study , patient divide two group . In Group A , patient continue entecavir another 72 week . In Group B , patient switch peg-interferon-2a monotherapy 48 week , follow 24 week .</brief_summary>
	<brief_title>Efficacy Peg-interferon α-2a Hepatitis B Patients Treated Entecavir Without HBeAg Loss</brief_title>
	<detailed_description>For HBeAg positive hepatitis B patient treat entecavir 48 week without HBeAg loss , switch peg-interferon may increase response rate . In study , patient without HBeAg loss 48 week entecavir treatment divide two group . In Group A , patient continue entecavir another 72 week . In Group B , patient switch peg-interferon-2a monotherapy 48 week , follow 24 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Age 18 50 year old HBsAg ( + ) HBeAg ( + ) 6 month entecavir treatment Treated entacavir 48 week HBeAg seroconversion Pregnant woman Decompensated liver disease Combination infection HCV , HAV , HEV Combination infection HIV Any contraindication interferon α</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>sequential peg-interferon-2a entecavir</keyword>
</DOC>